This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Number of treatment-emergent adverse events (TEAE)
Timeframe: From baseline (week 0) to end of study (up to week 44)
Part B: Relative change in body weight
Timeframe: From baseline (week 0) to end of treatment (week 36)
Part C: Occurrence of premature treatment discontinuation (Yes/No)
Timeframe: At end of treatment (week 24)